📰 Open Label Phase News
Page 2 - Open Label Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Open Label Phase. Real-time updates on events, politics, business and more.
October 31, 2023
Four late-breaking clinical trial outcomes from The VEINS Conference presented results from the CLOUT Registry, VIVID Trial, DEXTERITY-AFP Trial, and Venous Thromboembolism Treatment were present during the The VEINS Conference, taking place Oct. 28-30 in Las Vegas, NV.
October 30, 2023
/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...
September 29, 2023
Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)
September 29, 2023
Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology...
September 22, 2023
ZURICH, Sept. 22, 2023 /PRNewswire/ -- Takeda (TSE:4502) (NYSE:TAK) today announced the European Medicines...
September 13, 2023
Disease Landscape Insights equips healthcare pioneers with the tools to combat ringworm early stages, providing in-depth diagnostic, treatment, and market...
August 30, 2023
/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...
August 11, 2023
BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...
June 14, 2023
Supplemental New Drug Application (sNDA) submission based on the NAPOLI 3 Phase III trial1Approval would represent expansion of treatment options in an aggressive and difficult-to-treat cancer with few
June 14, 2023
Supplemental New Drug Application submission based on the NAPOLI 3 Phase III trial1Approval would represent expansion of treatment options in an aggressive and difficult-to-treat cancer with few... | June 14, 2023